Abstract
Hormone therapy including hormone replacement therapy (HRT), oral contraceptive pills (OCPs), and testosterone is commonly used. OCPs and HRT are associated with an increased risk of venous thromboembolism (VTE). Perioperative consultants may be asked to provide recommendations for the risks and/or management of these medications perioperatively. This chapter provides an overview of risks of use of hormone therapy around the time of surgery and suggestions for management.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Lidegaard O, et al. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ. 2011;343:d6423.
Canonico M, et al. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ. 2008;336:1227.
Canonico M, et al. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: sytematic review an meta-analysis. BMJ Online First. 2008;336:1227.
Cushman M, et al. Estrogen plus progestin and risk of venous thrombosis. JAMA. 2004;292(13):1573.
Anderson GL, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Womans health initiative randomized controlled trial. JAMA. 2004;291(14):1701.
Wierckx K, et al. Long-term evaluation of cross-sex hormone treatment in transexual persons. J Sex Med. 2012;9:2641–51.
Maged Y, et al. Association of testosterone replacement therapy and the incidence of a composite of postoperative in-hospital mortality and cardiovascular events in men undergoing noncardiac surgery. Anesthesiology. 2017;127:457–65.
de Bastos M, et al. Combined oral contraceptives: venous thrombosis. Cochrane Database Syst Rev. 2014;(3):CD010813.
Vandenbroucke JP, et al. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet. 1994;344(8935):1453.
van Vlijmen EF, et al. Oral contraceptives and the absolute risk of venous thromboembolism in women with single or multiple thrombophilic defects: results from a retrospective family cohort study. Arch Intern Med. 2007;167(3):282.
Hussain T, Kneeshaw PJ. Stopping tamoxifen peri-operatively for VTE risk reduction: a proposed management algorithm. Int J Surg. 2012;10(6):313–6. https://doi.org/10.1016/j.ijsu.2012.05.001. Epub 2012 May 16.
Ellis AJ, Hendrick VM, Williams R, Komm BS. Selective estrogen receptor modulators in clinical practice: a safety overview. Expert Opin Drug Saf. 2015;14(6):921–34.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Pratt, A. (2020). Hormone Therapy. In: Jackson, M., Huang, R., Kaplan, E., Mookherjee, S. (eds) The Perioperative Medicine Consult Handbook. Springer, Cham. https://doi.org/10.1007/978-3-030-19704-9_15
Download citation
DOI: https://doi.org/10.1007/978-3-030-19704-9_15
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-19703-2
Online ISBN: 978-3-030-19704-9
eBook Packages: MedicineMedicine (R0)